Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brands: LYRICA, LYRICA CR
Published 2025-12-22 · Last reviewed 2025-12-29 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Pregabalin is an α2δ calcium-channel ligand (brand Lyrica) approved for several neuropathic pain syndromes, fibromyalgia, and adjunctive therapy for partial-onset seizures (label). While it is approved for generalized anxiety disorder in many countries, U.S. psychiatric use is off label.
In psychiatric practice, pregabalin is typically used as a sedating adjunct for anxiety symptoms and sleep continuity—often when clinicians want an alternative to benzodiazepines or when comorbid pain is prominent.
Compared with gabapentin, pregabalin has more predictable absorption and is often dosed BID, which may contribute to a perception of faster onset. The trade-off is higher rates of dizziness, edema, and weight gain in many cohorts.
Pregabalin has negligible metabolism and is cleared renally; renal function is the key dosing constraint. Declining eGFR can present as oversedation, confusion, and falls.
Pregabalin is Schedule V in the U.S. Misuse/diversion and co-use with opioids/other sedatives increase risk; treat early refills, escalating doses, and intoxication as safety signals and avoid automatic refills.
The pregabalin compare view, pregabalin evidence feed, and pregabalin print page can support aligning anxiety/sleep adjuncts with sedation, edema, and misuse risk.
Pregabalin can be clinically effective for “somatic anxiety” and sleep continuity in some patients, but its controlled-substance status, misuse risk, and metabolic/edema liabilities require explicit safeguards. Treat it as a time-limited adjunct with clear targets and follow-up; avoid escalating doses in response to tolerance without revisiting diagnosis and first-line therapies.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Binds the α2δ subunit of voltage-gated calcium channels, reducing calcium-dependent release of excitatory neurotransmitters; it does not directly bind GABA-A receptors despite the name.
Clinical benefits in anxiety likely reflect reduced physiologic hyperarousal and improved sleep continuity; response should be evaluated alongside daytime functioning and sedation burden.
Because sedation is common, improvement in “anxiety” may reflect tranquilization rather than meaningful cognitive symptom change; pair use with psychotherapy and primary anxiety pharmacotherapy when needed.
Sources: FDA/DailyMed label; generalized anxiety disorder reviews/meta-analysis; misuse/diversion systematic review update.